Autonomix Expands Canadian Patent Protection for Catheter-Based Nerve Monitoring and Therapy

Autonomix Medical has secured Canadian Patent No. 3,183,802 covering catheter-based systems designed to access, monitor and treat tissue through a vessel or other bodily lumen wall. The technology combines multi-site electrophysiological sensing with feedback-guided therapy, allowing a catheter-based system to assess neural activity and potentially adjust treatment in real time. Autonomix announced the Canadian patent on October 2, 2026, although the Canadian patent record shows the grant was formally published on May 12, 2026.

A Catheter That Can Reach Beyond the Vessel Wall

Some of the hardest targets in minimally invasive medicine are not inside the blood vessel itself. Nerves and other tissues can sit within or beyond the vessel wall, making them difficult to reach without more invasive procedures.

Autonomix Medical is developing a platform designed to approach those targets from inside a bodily lumen. Its newly announced Canadian patent protects systems in which a catheter carries deployable probes that can extend into or through the lumen wall to interact with nearby tissue and nerves.

The approach is part of Autonomix’s broader effort to develop minimally invasive, nerve-targeted therapies. The company is initially focusing on pain associated with pancreatic cancer, while describing potential applications across other conditions in which abnormal nerve activity plays a role.

What Canadian Patent No. 3,183,802 Covers

The patent, titled “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through a Lumen Wall,” covers technology for monitoring and modifying electrophysiological activity from within a bodily lumen.

In practical terms, a catheter can carry one or more small probes toward a target. Those probes can be deployed through the wall of a vessel or other lumen to reach tissue outside the lumen.

The patent describes electrodes and sensing components capable of collecting electrophysiological signals from multiple locations. These can include a target location, a secondary location and a reference location, providing additional information for interpreting neural activity during a procedure.

The patent also covers processing those signals to help determine whether a procedure has produced its intended physiological effect.

That distinction is important. The technology is not simply about delivering energy to tissue. It is designed around a broader sense, treat and verify concept in which physiological information can help guide and assess the intervention.

Real-Time Feedback Could Change How Nerve Procedures Are Guided

One of the more significant elements of the patent is its coverage of closed-loop control.

In a conventional procedure, a physician may deliver therapeutic energy according to a predetermined plan and then assess the result using available clinical measurements. A closed-loop system instead uses incoming physiological information to influence what happens next.

Autonomix says its patented technology can use electrophysiological feedback to adjust stimulation or therapeutic energy delivery in real time. The patent also describes systems capable of evaluating procedural completion based on changes in neural activity.

This could create a feedback pathway:

Locate the target → measure neural activity → deliver therapy → measure the response → adjust or confirm the procedure.

The patent itself covers the technology architecture and methods. It does not mean that every capability described in the patent has already been demonstrated as an approved clinical product.

The Technology Is Designed Around Nerve Mapping

Autonomix’s broader platform combines catheter-based access with a microchip sensing array intended to detect and differentiate neural signals.

The company says the sensing system is designed to identify nerve activity with high sensitivity, after which its radiofrequency technology can be used to target nerves.

This is particularly relevant to procedures where the physician needs to locate a specific nerve bundle rather than simply treat a visually identifiable anatomical structure.

The underlying Canadian patent is broad enough to describe monitoring nerves and neural structures associated with areas including the renal, celiac, carotid, pancreatic and other nerve plexuses.

Pancreatic Cancer Pain Is the Initial Clinical Focus

Autonomix’s first clinical application is pancreatic cancer-related pain.

Pancreatic cancer can produce severe pain partly through involvement of nerve networks around the pancreas. Autonomix is investigating whether transvascular radiofrequency ablation can disrupt relevant nerve pathways while avoiding more invasive access routes.

Its first-in-human proof-of-concept study enrolled 20 patients with severe abdominal pain from unresectable pancreatic cancer. The company reported meaningful pain reductions following treatment and subsequently expanded its program toward additional visceral cancers and earlier-stage pancreatic cancer patients with moderate to severe pain.

However, an important distinction remains: the patented sensing array was not used in that initial PoC 1 study. The company has said the trial evaluated transvascular RF ablation, while the catheter-based microchip sensing technology is intended for evaluation in future studies.

That means the Canadian patent should not be interpreted as evidence that the complete sensing-and-feedback system has already been clinically validated.

From Pain Management to a Broader Platform

Autonomix is positioning the technology as a platform rather than a device designed for only one disease.

The company’s stated areas of potential expansion include other forms of chronic pain, hypertension and cardiology, along with additional visceral applications. Its current development strategy includes expanding evaluation into cancers involving the pancreatic, gallbladder, liver and bile-duct regions.

The underlying idea is that many diseases involve abnormal nerve signaling. If a catheter can reach those nerve pathways through the vasculature and provide useful physiological feedback, the same basic architecture could potentially be adapted to different anatomical targets.

That remains a development strategy rather than an established clinical capability.

The Canadian Patent Strengthens Global Intellectual Property Protection

The Canadian grant adds another jurisdiction to Autonomix’s patent portfolio.

The company said its global portfolio contained 112 issued or pending patent applications when the Canadian patent was announced in October. Related patents covering aspects of the technology had previously been issued in the United States and Europe.

The underlying Canadian patent application dates back much further. The patent family has a priority date of November 5, 2012, while the Canadian application associated with Patent No. 3,183,802 was filed in 2013. The Canadian patent record shows the granted patent, CA3183802C, was published on May 12, 2026.

Autonomix publicly announced the Canadian grant on October 2, 2026, which explains why the milestone is being reported as part of the company’s October 2026 intellectual-property update.

A Patent Is Not the Same as Regulatory Approval

The distinction between intellectual-property protection and medical approval is particularly important for this technology.

A patent protects an invention or defined aspects of its implementation. It does not establish that the technology is safe, effective or authorized for routine clinical use.

Autonomix explicitly states that its technology remains investigational and has not been cleared for marketing in the United States. The company is continuing clinical and preclinical development as it works toward future regulatory submissions.

The Canadian patent therefore represents an intellectual-property milestone, while the larger medical question—whether the complete platform can reliably identify nerves, guide therapy and improve patient outcomes—still depends on further clinical evidence.

What the Technology Could Mean for Minimally Invasive Neuromodulation

The larger scientific and engineering challenge is not simply reaching a nerve. It is knowing precisely where the target is, understanding its activity and determining whether the treatment produced the intended physiological change.

Autonomix’s patented architecture attempts to combine those steps within a catheter-based workflow.

If future studies validate the sensing, treatment and feedback components together, such a system could offer physicians a more data-driven way to perform selected nerve-targeted procedures without requiring direct surgical access to the target.

For now, the Canadian patent marks a strengthening of the technology’s intellectual-property position—not the final validation of the clinical concept.

The next meaningful milestones will therefore come from clinical evidence, regulatory progress and demonstrations of the integrated sensing-and-treatment platform, rather than from the patent grant alone.